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Introduction {#sec005}
============

New-borns with very low birth weight show an increased risk of necrotising enterocolitis (NEC) \[[@pone.0226496.ref001]\], systemic sepsis \[[@pone.0226496.ref002], [@pone.0226496.ref003]\] and other clinical complications that may lead to infant mortality, short-term complications or even persistent, life-long sequelae. These include bronchopulmonary dysplasia (BPD) \[[@pone.0226496.ref004], [@pone.0226496.ref005]\], retinopathy of prematurity (RoP) and neurodevelopmental problems \[[@pone.0226496.ref006]\]. While time trends suggest some improvements in the rates of sepsis and RoP, NEC rates remain constant and BPD rates have slightly increased \[[@pone.0226496.ref007]\]. Additionally the complications following a very low birth weight birth constitute 1.4 percent of all new-borns, corresponding to 11,051 very low birth weight babies in 2017 in Germany \[[@pone.0226496.ref008]\]. This number has remained relatively constant over time.

The feeding of very low birth weight babies seems to play a major role in the risk of developing complications and mother's milk seems to have a protecting effect against these complications compared to infant formula \[[@pone.0226496.ref009]--[@pone.0226496.ref014]\]. However, very low birth weight babies have a substantially greater requirement for a number of nutrients compared to full term babies. This larger demand is not met by mother's own milk or milk from donor milk banks \[[@pone.0226496.ref015]\], making the use of fortifiers necessary as a supplement to the milk \[[@pone.0226496.ref016], [@pone.0226496.ref017]\]. Human milk fortifiers and preterm formulas routinely used in neonatal feeding are derived from cow's milk, but recently fortifiers produced from donor mother's milk have become available. The feeding of very low birth weight babies with this exclusive human milk diet (EHMD) has shown a reduction in NEC, sepsis, BPD, RoP and mortality compared to cow milk-based nutrition \[[@pone.0226496.ref018]--[@pone.0226496.ref021]\].

In addition to the significant complications of a very low birth weight birth, the health care utilization of those babies also comes with high economic costs. Taking newborns with a birth weight of 750-999g as an example, the immediate inpatient care in neonatal intensive care units or regular care units including no significant operating procedure has a mean cost of €72,702 in Germany and increases to €121,594 for a birth weight below 600g \[[@pone.0226496.ref022]\]. The long-term effects were found to be €120.60 per patient per year for direct health care costs \[[@pone.0226496.ref023]\]. Reducing the complication rates associated with a very low birth weight birth may also lead to a reduction in the expenditure for neonatal and long-term care of these infants.

The aim of the current paper is to estimate the cost-effectiveness of an EHMD compared to the current nutritional practice for very low birth weight infants in Germany, taking into account short-term and long-term outcomes, as measured by life-years gained, and costs.

Methods {#sec006}
=======

Model layout & natural history {#sec007}
------------------------------

The model has been constructed as a decision tree as depicted in [Fig 1](#pone.0226496.g001){ref-type="fig"}. For an EHMD or the current feeding strategy, very low birth rate neonates have a probability of developing NEC (ICD-10 P77) \[[@pone.0226496.ref024]\], sepsis (ICD-10 P36) \[[@pone.0226496.ref025]\], NEC and sepsis or no complication at all and may either survive or die from these health states or for other reasons \[[@pone.0226496.ref026]\]. NEC may be treated medically or surgically, and the latter may lead to short-bowel syndrome (SBS; ICD-10 K91.2) \[[@pone.0226496.ref027]\]. All such surviving newborns are additionally at risk of developing retinopathy of prematurity (RoP; ICD-10 H35.1) \[[@pone.0226496.ref026]\], bronchopulmonary dysplasia (BPD; ICD-10 P27.1) \[[@pone.0226496.ref028]\], cerebral palsy (ICD-10 G80) \[[@pone.0226496.ref006], [@pone.0226496.ref029]\] or other neurological impairments \[[@pone.0226496.ref006]\]. As the risks of these complications are dependent on the birth weight of the infant, the cohort running through the model has been stratified by birth weight: "\<500g", "500-749g", "750-999g", "1000-1249g" and "1250 -1499g". The time-horizon is life-long as all costs and outcomes are followed until the death of the cohort entering the model.

![Decision tree of the model.\
For a better overview of the tree, the following simplifications were made in the above figure: Branches marked with an asterisk (\*) follow the same branch as from the state "NEC medical". Death branches include health-state specific mortality as well as background mortality. (EHMD: exclusive human milk diet, BOV: cow milk-based nutrition, NEC: necrotising enterocolitis, Tx: treatment, RoP: retinopathy of prematurity, BPD: bronchopulmonary dysplasia, SBS: short bowel syndrome).](pone.0226496.g001){#pone.0226496.g001}

The model population consists of the average, yearly number of very low birth weight newborns in Germany from the years 2012 to 2016 \[[@pone.0226496.ref030]--[@pone.0226496.ref034]\]. The probabilities of the different health states and complications are given in [Table 1](#pone.0226496.t001){ref-type="table"} for the overall cohort for the standard nutritional strategy. The birth weight-specific values can be found in the supplement. Wherever possible, health state specific probabilities of complications were directly calculated from extracted, stratified case numbers reported in various studies. When this was not possible (i.e. for the probabilities of NEC alone, sepsis alone and RoP given NEC and sepsis, respectively), relative risks have been calculated from available studies \[[@pone.0226496.ref026], [@pone.0226496.ref027]\] and were applied to German datasets to retrieve health state specific complication probabilities. Clopper-Pearson intervals for confidence intervals (CIs) on proportions have been calculated for parameters from studies without a control group. For studies with control groups, the CIs were calculated using a normal approximation with unequal group sizes.

10.1371/journal.pone.0226496.t001

###### Medical model parameters.

![](pone.0226496.t001){#pone.0226496.t001g}

  Parameter                                       Mean                                                     Range DSA       Distribution for PSA                        Source
  ----------------------------------------------- -------------------------------------------------------- --------------- ------------------------------------------- ----------------------------------------------------
  Cohort size                                     9,519                                                    8,136--10,903                                               \[[@pone.0226496.ref030]--[@pone.0226496.ref034]\]
  Probability NEC\*                               5.7%                                                     4.9%--6.5%      Dirichlet (Gamma(1;543))                    \[[@pone.0226496.ref024]\]
  \- *NEC surgical*                               25.1%                                                    21.8%--28.7%    Beta (682.05;2030.95)                       \[[@pone.0226496.ref025]\]
  \-- *NEC surgical BPD*                          7.2%                                                     6.7%--7.8%      Beta (689.33;8829.07)                       \[[@pone.0226496.ref030]--[@pone.0226496.ref034]\]
  \-- *NEC surgical SBS*                          19.4%                                                    15.9%--23.3%    Beta (88.81;369.19)                         \[[@pone.0226496.ref027]\]
  \-- *NEC surgical RoP\**                        9.0%                                                     7.4%--10.8%     Beta (1,178.93;11,967.07)                   \[[@pone.0226496.ref026]\]
  \-- *NEC surgical Cerebral Palsy*               23.8%                                                    17.7%--30.9%    Beta (40.76;130.24)                         \[[@pone.0226496.ref006], [@pone.0226496.ref029]\]
  \-- *NEC surgical Neurological*                 39.3%                                                    21.5%--59.4%    Beta (10.61;16.39)                          \[[@pone.0226496.ref006]\]
  \- *NEC medical*                                74.9%                                                    71.3%--78.2%    Complementary probability to NEC surgical   
  \-- *NEC medical BPD*, *RoP\**                  \- Same as NEC surgical -                                                                                            
  \-- *NEC medical Cerebral Palsy*                11.6%                                                    7.4%--17.1%     Beta (21.88;166.12)                         \[[@pone.0226496.ref006], [@pone.0226496.ref029]\]
  \-- *NEC medical Neurological*                  23.1%                                                    11.1%--39.3%    Beta (8.77;29.23)                           \[[@pone.0226496.ref006]\]
  \- *NEC surgical and medical mortality*         10.9%                                                    6.1%--15.7%     Beta(118.68;972.32)                         \[[@pone.0226496.ref002]\]
  \- *Background mortality*                       \- Same as No complication mortality -                                                                               
  Sepsis\*                                        12.7%                                                    12.1%--13.2%    Dirichlet Gamma(1;1,206))                   \[[@pone.0226496.ref025]\]
  \-- *Sepsis BPD*                                \- Same as NEC surgical -                                                                                            
  \-- *Sepsis RoP\**                              2.8%                                                     2.3%--3.4%      Beta (368.02;12,777.98)                     \[[@pone.0226496.ref026]\]
  \-- *Sepsis Cerebral Palsy*                     19.5%                                                    6.7%--32.3%     Beta (51.56;212.44)                         \[[@pone.0226496.ref006], [@pone.0226496.ref035]\]
  \-- *Sepsis Neurological*                       35.9%                                                    29.9%--42.3%    Beta (87.64;156.36)                         \[[@pone.0226496.ref006]\]
  \- *Sepsis mortality*                           17.5%                                                    23.3%--23.6%    Beta(32.83;155.17)                          \[[@pone.0226496.ref036]\]
  \- *Background mortality*                       \- Same as No complication mortality -                                                                               
  Sepsis + NEC                                    2.3%                                                     1.8%--2.8%      Dirichlet (Gamma(1;217))                    
  \- Sepsis + NEC surgical                        \- Same as NEC surgical -                                                                                            
  \-- *Sepsis + NEC surgical BPD*, *RoP*, *SBS*   \- Same as NEC surgical -                                                                                            
  \-- *Sepsis + NEC surgical Cerebral Palsy*      21.4%                                                    4.7%--50.8%     Beta (2.79;10.21)                           \[[@pone.0226496.ref006]\]
  \-- *Sepsis + NEC surgical Neurological*        50.0%                                                    23.0%--77.0%    Beta (6.50;6.50)                            \[[@pone.0226496.ref006]\]
  \- Sepsis + NEC medical                         \- Same as NEC medical -                                                                                             
  \-- *Sepsis + NEC medical BPD*, *RoP*           \- Same as NEC medical -                                                                                             
  \-- *Sepsis + NEC medical Cerebral Palsy*       20.0%                                                    5.7%--43.7%     Beta (3.80;15.20)                           \[[@pone.0226496.ref006]\]
  \-- *Sepsis + NEC medical Neurological*         45.0%                                                    23.1%--68.5%    Beta (8.55;10.45)                           \[[@pone.0226496.ref006]\]
  \- *Sepsis + NEC surgical mortality*            \- Combined probabilities of Sepsis and NEC surgical -                                                               
  \- *Sepsis + NEC medical mortality*             \- Combined probabilities of Sepsis and NEC medical -                                                                
  \- *Background mortality*                       \- Same as No complication mortality -                                                                               
  No NEC or sepsis                                79.3%                                                    77.4%--81.1%    Dirichlet Gamma(1;7,553))                   
  \-- *No NEC or sepsis BPD*                      \- Same as NEC surgical -                                                                                            
  \-- *No NEC or sepsis RoP\**                    2.8%                                                     2.3%--3.4%      Beta (368.02;12,777.98)                     \[[@pone.0226496.ref026]\]
  \-- *No NEC or sepsis Cerebral Palsy*           15.0%                                                    12.6%--17.6%    Beta (120.85;687.15)                        \[[@pone.0226496.ref006]\]
  \-- *No NEC or sepsis Neurological*             22.0%                                                    19.2%--25.0%    Beta (177.78;630.22)                        \[[@pone.0226496.ref006]\]
  \- *No complication mortality*                  14.9%                                                    13.7%--16.2%    Beta (838.92;5,752.05)                      \[[@pone.0226496.ref026]\]

Parameters marked with a \* are calculated using relative risks from other studies. (DSA: deterministic sensitivity analysis, PSA: probabilistic sensitivity analysis, NEC: necrotising enterocolitis, BPD: bronchopulmonary dysplasia, SBS: short bowel syndrome, RoP: retinopathy of prematurity)

Intervention {#sec008}
------------

An EHMD is administered dependent on the birth weight of the infant following the feeding protocol of the Texas Children's Hospital (TCH) in the base case \[[@pone.0226496.ref037]\]. In general, all feeding schemes start with a trophic feed, followed by an incremental increase in the feeding volume measured in ml per kg per day and then fortification. Upon reaching a specific weight goal and/or gestational age the new-borns are assumed to receive full feeds of 150ml/kg/day. Subsequently the infant is weaned off the human milk-derived fortifier over a four day period. In the base case, Prolact+6 is mixed with mother's milk in a 30ml to 70ml ratio. In a lesser fortification case, Prolact+4 is used in a ratio of 20/80ml and in the higher case a ratio of 40/60ml is assumed with Prolact+8.

The efficacy of EHMD has been taken from three different studies showing a relative risk (RR) of 40.0% \[95% CI 30.4%--52.8%\] against NEC \[[@pone.0226496.ref020], [@pone.0226496.ref038]\], 45.2% \[95% CI 18.1%--113.1%\] against surgical NEC \[[@pone.0226496.ref020], [@pone.0226496.ref038]\], 68.0% \[95% CI 58.1%--79.5%\] against sepsis \[[@pone.0226496.ref020], [@pone.0226496.ref038]\], 84.9% \[95% CI 77.2%--93.3%\] against BPD \[[@pone.0226496.ref038]\] and 55.1% \[95% CI 38.4%--78.9%\] against RoP \[[@pone.0226496.ref021], [@pone.0226496.ref038]\]. Study results are not yet available on the effectiveness of an EHMD on neurological sequelae, as these can only be assessed later in life. To explore the possible impact of an EHMD on the neurological development of very low birth weight infants, we evaluated a scenario with a RR of 0.90 against cerebral palsy and other neurological impairments. For the EHMD strategy, these RRs are applied to the corresponding parametric values in [Table 1](#pone.0226496.t001){ref-type="table"}. The study population in Hair et al. (2016) included only infants between 750g and 1,250g. A specific analysis was carried out in the sensitivity analyses by calculating the results only for these weight groups.

Costs {#sec009}
-----

The cost of an EHMD was dependent on the weight-specific feeding scheme and is calculated with a price of €6 per ml for the fortifier. In the base case analysis it was assumed that the fortifier is added to the milk produced by the mother. The overall EHMD costs amount to €6,812 per person over all weight groups, i.e. the cost are €13,015 for infants \<500g, €11,895 for 500-749g, €9,106 for 750-999g, €5,208 for 1,000--1,249g and €3,246 for the birth weight group of 1,250-1499g. Using milk from a donor milk bank at a price of €65 per litre (range €60 to €90; personal communication with German milk bank in Leipzig) was explored as a scenario in the sensitivity analyses. For the standard care strategy, no additional costs were incorporated into the model, as they were already included in the diagnosis-related groups (DRGs). Two additional feeding scenarios (using less and more fortifier, respectively) have been used as the lower and upper bound for the costs of an EHMD, but assuming the same degree of effectiveness.

The costs for each health state were calculated via a price-resources framework for inpatient stays. The length of stay (LOS) was been extracted for each ICD code from the database of the Federal Statistical Office covering the period 2006 and 2016 \[[@pone.0226496.ref039]\] and the mean LOS was combined with the corresponding Diagnosis Related Groups (DRGs) \[[@pone.0226496.ref022]\] to calculate the inpatient costs using the base rate of €3,376 for the year 2017 \[[@pone.0226496.ref040]\]. As the ICD-specific LOS data stratified by birth weight were not available, adjustment factors have been calculated from another German data source on LOS for very low birth weight infants by calculating the ratio of the LOS of the different birth weight categories and the overall LOS of all newborns with a birth weight between 500g and 1499g \[[@pone.0226496.ref025]\]. Costs for complications (BPD, SBS, RoP) were calculated accordingly and added to the health state-specific costs. Lifetime, direct health care costs were retrieved from a German study \[[@pone.0226496.ref041]\] for cerebral palsy (€232,703 at 3% discounting) and for other neurological impairments (€94,220).

For the societal perspective, indirect costs were calculated using the human capital approach, including the forgone productivity due to death or disability measured by the discounted life-time earnings of a newborn and the productivity loss of one parent during the inpatient stay. A scenario of the friction cost approach has also been applied. Using this approach, one parent staying with the newborn has a productivity loss for the friction period of 92 days \[[@pone.0226496.ref042]\]. The reference year of all costs is 2017.

Analysis {#sec010}
--------

The base case analysis was conducted from a third-party payer (TPP) perspective with 3% discount rates on costs and LYG using the TCH (+6) feeding scheme for EHMD and the friction cost approach as recommended by German guidelines \[[@pone.0226496.ref043]\]. Discount rates of 0% and 5% as well as a societal perspective were also explored. In the absence of an official threshold of the maximal acceptable willingness-to pay for an additional LYG, the GDP per capita (\$50,878/€45,790 \[[@pone.0226496.ref044], [@pone.0226496.ref045]\]) from the recommendations of the World Health Organization (WHO) was used \[[@pone.0226496.ref046]\]. Further deterministic sensitivity analyses (DSA) were conducted by setting parameters at their lower and upper bound, which were set from the 95% CIs wherever possible. Break-even analyses have been performed on the probabilities for NEC and sepsis for a threshold of €50,000/LYG in order to explore the robustness of the cost-effectiveness calculation. A probabilistic sensitivity analysis (PSA) was conducted using the probability distributions given in [Table 1](#pone.0226496.t001){ref-type="table"} and the appendix, drawing 1,000 parametric values from those distributions. The probabilities of the intervention being cost-effective were calculated for willingness-to-pay (WTP) thresholds from €0 to €100,000 per LYG and have been plotted as cost-effectiveness acceptability curves (CEACs). Additionally, an expected value of perfect information (EVPI) analysis was conducted to estimate the cost-effectiveness of further research. Internal validity of the model was checked by calculating the results of the total population once directly and one via weighted averages over the different birth weight strata. All analyses were conducted in Microsoft Excel 2013.

Results {#sec011}
=======

In the base case analysis, assuming the Texas Children's Hospital+6 feeding strategy, a third party payer (TPP) perspective and no use of donor milk, the cost-effectiveness of EHMD is €35,464 per LYG. Using the friction cost approach, the corresponding value for the societal perspective is €33,991/LYG. The cost-effectiveness from a societal perspective using the human capital approach improves to €9,681/LYG. The sub-group analysis for the different birth weight groups reveals an association between lower birth weight and a more favourable ICER. The ICER is €16,272/LYG in the base case for infants in the "\<500g" group and increases to €70,910/LYG in the category "1250-1499g". The cost-effectiveness for the clinical study population based on an EHMD (750g to 1249g) is €34,016/LYG from a TPP perspective and €32,061/LYG or €8,183/LYG from a societal perspective using the friction cost or the human capital approach. Detailed results for the base case can be found in [Table 2](#pone.0226496.t002){ref-type="table"}.

10.1371/journal.pone.0226496.t002

###### Direct and indirect costs and life years lost for the different birth-weight groups of the study population for the base case.

![](pone.0226496.t002){#pone.0226496.t002g}

                           Direct Costs per patient   Indirect Costs per patient   Life years lost   ICER                               
  ------------ ----------- -------------------------- ---------------------------- ----------------- -------- ------- ------- --------- ---------
  \<500g       *475*       €64,148                    €91,242                      €4,345            €2,715   20.91   19.24   €15,293   €16,272
  500-749g     *1*,*540*   €87,103                    €112,021                     €7,054            €4,608   13.88   12.72   €19,274   €21,371
  750-999g     *2*,*004*   €97,283                    €121,688                     €8,645            €6,368   6.89    5.91    €22,579   €24,882
  1000-1249g   *2*,*166*   €64,585                    €84,083                      €3,838            €3,573   2.45    2.14    €62,076   €62,931
  1250-1499g   *3*,*335*   €58,736                    €76,596                      €3,487            €3,863   1.40    1.15    €72,402   €70,910
  Total        *9*,*519*   €73,041                    €94,254                      €5,273            €4,391   5.79    5.19    €33,991   €35,464

(ICER: incremental cost-effectiveness ratio, EHMD: exclusive human milk diet, TPP: third-party payer)

The deterministic sensitivity analyses (i.e. setting input parameter values to their lower and upper bounds) reveal the probability for death due to sepsis and the efficacy with regards to mortality reduction to be the most influential parameters on the ICER value. Setting the sepsis mortality to the lower bound of 12.3% yields an ICER of €43,703/LYG, and €29,043/LYG for the upper bound of 23.6%. However, changing the RR for the health state-specific mortality yields ICERs of €44,902 and €30,584/LYG for the lower (0.90) and upper bounds (0.57), respectively. As can be seen in [Fig 2](#pone.0226496.g002){ref-type="fig"}, the probabilities of the health states and the effectiveness of an EHMD are found among the most influential parameters. Assuming different feeding strategies has only a minor effect on the ICER (see Price EHMD). The conservative feeding strategy results in an ICER of €31,548/LYG and the higher dosage of the fortifier results in an ICER of €36.612/LYG. No single parameter leads to the ICER being above the WTP threshold of €45,790/LYG.

![Tornado plot for all input parameters with an influence of more than €1,000 on the incremental cost-effectiveness ratio (ICER).\
(RR: relative risk, NEC: necrotising enterocolitis, EHMD: exclusive human milk diet).](pone.0226496.g002){#pone.0226496.g002}

In the scenario analyses, further changes to the model assumptions have been explored. Firstly, assuming the use of donor milk instead of mothers own milk for an EHMD, slightly increases the ICER to €35,867/LYG from a TPP perspective and to €34,394/LYG from a societal perspective. Secondly, the costs of the formula in the current feeding have explicitly been included in the model to reflect the replacement of currently used formula by an EHMD. Including costs of the current formula at a price of €20 per 200g (overall €223 per infant), the ICER would decrease to €35,091/LYG from a TPP perspective and to €33,618/LYG from a societal perspective with the friction approach. If no protective effect of an EHMD against neurological impairments and cerebral palsy was assumed, the cost-effectiveness increased to €43,459/LYG from a TPP perspective (€42,110/LYG from a societal perspective).

Furthermore, several break-even analyses were conducted to evaluate the influence of key parameters beyond their statistical uncertainty had on the ICER. As the probability of NEC was from a non-German source, the NEC probability has been lowered below the lower 95% CI of 4.9 percent down to zero. The ICER for this scenario was €52,762/LYG, while increasing the probability of NEC leads to improvements of the base case ICER. The probability of sepsis would need to be set to 5.5 percent (lower 95% CI in the base case: 12.1 percent) for the ICER to reach the WTP threshold of €45,790. The costs of an EHMD could be increased by approximately 25% (i.e. €8,516 per new-born) above the base case costs before the cost-effectiveness would be above the WTP threshold.

The result of the PSA for 1,000 model runs is shown in [Fig 3](#pone.0226496.g003){ref-type="fig"} in the form of a CEAC. Until a WTP threshold of €25,000/LYG, the probability for an EHMD being cost-effective is close to zero. After this threshold, the probability of an EHMD being cost-effective shows a steep incline, until the probability of EHMD being cost-effective reaches 97 percent at a threshold of €60,000/LYG. Eighty-one percent of the 1,000 model runs show an EHMD to be cost-effective at the WTP threshold of €45,790/LYG.

![Cost-effectiveness acceptability curve for 1,000 model iterations.](pone.0226496.g003){#pone.0226496.g003}

Based on these model iterations of the PSA, the population EVPI has been calculated and the results are shown in [Fig 4](#pone.0226496.g004){ref-type="fig"}. At the maximal WTP threshold of €45,790/LYG, the population EVPI corresponds to €5,610,000, or €589 per new-born per year. Conducting future research for this amount may potentially be cost-effective if the WTP threshold is above €31,000/LYG and below or equal the maximal WTP threshold.

![Expected value of perfect information for the population of 9,519 very low birth weight new-borns per year in Germany.](pone.0226496.g004){#pone.0226496.g004}

Discussion {#sec012}
==========

The results of this modelling study need to be interpreted in the light of several limitations. First of all, the study population of the clinical studies used for the EHMD efficacy is from the US and does not entirely match the German model population in terms of clinical complications and birth weight. The results for the birth weight subgroups from the clinical studies was very similar to the overall cost-effectiveness (€35,464 vs. €34,016 per LYG, respectively), but it remains unclear if the effectiveness estimates can be transferred to infants with birth weights below 750g or above 1,250g. The transferability of our results is also limited with regard to other countries due to the specific NEC rates, the German reimbursement scheme for inpatient costs and the cost of human milk and fortifiers in Germany. Secondly, the control group in the clinical studies received mother's milk with a bovine milk-based fortifier. As feeding protocols may vary between hospitals, it is unclear if all very low birth weight infants in Germany currently receive the exact same feeding as the control group of the studies considered. However, the current guidelines only mention bovine-based fortifiers \[[@pone.0226496.ref016]\] and it can be reasonably assumed that the infants represented by the German data used in the model were not fed using an EHMD. In this context it should also be stated that the effectiveness of an EHMD was only considered against the health state specific mortality. If a very low birth weight infant dies, there may be several conditions present that may have caused the death, making it hard to calculate health-state specific mortality rates. Thus, there may be deaths in the model from background mortality that may also be prevented by an EHMD. Additionally, the mortality of newborns suffering from concurrent NEC and sepsis in the model is assumed to be the statistically independent combination of the respective NEC and sepsis mortalities when it may in fact be higher. This would lead to an underestimation of the effectiveness of an EHMD.

With regard to the main outcome of the model, LYG does not capture all consequences of a disease. Quality adjusted life-years (QALYs) are usually taken as the primary outcome in economic evaluation to cover not only mortality but also the morbidity associated with a disease. Unfortunately, the elicitation of utilities for the different health states in newborns is not easily possible and QALYs are, therefore, not available for the evaluation of interventions for these infants. This also implies that spill-over \[[@pone.0226496.ref047]\] and bereavement effects \[[@pone.0226496.ref048]\], i.e. a quality of life loss for parents by the disability or the death of their child, cannot be incorporated in the model.

The economic results of the model need also to be seen with respect to the medical outcomes of the model. While the EHMD strategy avoids around 290 deaths, there are more survivors who may suffer from long-term complications. While there are fewer cases of BPD, SBS and RoP for the EHMD strategy, there are 30 more cases of cerebral palsy and 25 more cases of other neurological impairments compared to the control. Further research may focus on the long-term effects of human milk-based fortifiers on the neurological development of these infants. The EVPI analysis revealed that this future research might be cost-effective under the current WTP threshold of up to €6 million per year.

Conclusions {#sec013}
===========

The EHMD strategy can be considered a cost-effective new treatment strategy for very low birth weight newborns in Germany from a TPP perspective under a maximal WTP threshold of €45,790/LYG. The deterministic as well as the probabilistic sensitivity analyses showed that this estimate is robust against a variety of changes to the input parameters values. Only decreasing the effectiveness against more than one complication concurrently makes the ICER increase above the WTP threshold of €45,790/LYG recommended by WHO for Germany.

Supporting information {#sec014}
======================

###### Supporting information.

This file contains a detailed list of all model parameters.

(PDF)

###### 

Click here for additional data file.
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Prem Shekhawat, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1.  Thank you for your funding statement; \"Both authors, SMS and WG, wish to disclose that the research on which our manuscript is based was funded by an unrestricted research grant by Prolacta BioSciences (<https://www.prolacta.com/>). The funder had no influece on the study design, data collection and analysis, decision to publish and the preparation of the manuscript. \"

We note that you received funding from a commercial source: Prolacta BioSciences

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other [relevant declarations](http://www.plosone.org/static/competing.action) relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Additional Editor Comments (if provided):

Thank you for your submission titled \"An Exclusive Human Milk Diet for Very Low Birth Weight New-borns -- a Cost-Effectiveness and EVPI Study for Germany\", it made interesting reading but needs major revision before it can be considered suitable for publication. The issues which must be addressed are:

1. Major English language corrections are required, there are too many problems which need fixing before it can be considered suitable for further review. I suggest hiring a language expert who should essentially rewrite the whole manuscript so that it becomes easy to read so that average reader can understand the meaning.

2\. Manuscript is statistics heavy, tables are too long, results presented in a very complex manner which are hard to understand for average reader of PLOS one, kindly shorten data, every single detail need not be provided but salient features are shown in tables, cutting back on some figures and tables will help.

3\. It should be very clear in results and discussion section that this study results are valid only to the local German population and cannot be applied universally since the NEC rate as well as cost of human milk fortifier are highly variable between centers. Likewise hospital charges are much different then actual cost of the product making this work difficult to use.

Kindly see attached comments by two experts in the field to revise your manuscript.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Line 34 : Please provide the expansion of LYG and ICER here

Line 48 : need to be BPD instead of BDP

Line 108-109 : what is meant by the statement\"in cost scenario for EHMD a ratio of 30/70 is assumed using Prolact+8 (with a ratio of 40/60)\". Why is it assumed as 30/70 when its 40/60

Line 115-116 : If there are no available data for the effectiveness of EHMD on neurological sequelae, based on what criteria was the RR of 0.90 assumed

Line 136-138 : What was the process used to calculate the LOS data based on birth weight? What is the adjustment factor and how was it arrived at?

Line 160 : Put WTP in parenthesis here so that the reader can recognize what it stands for later in the manuscript.

Line 177 - its showing both Table 2Table 1. which one is it? Table 2?

Table 2 : Please add \"for the base case\" in the legend.

Reviewer \#2: The feeding of very low birth weight babies seems to play a major role in the risk of developing complications. Scholz and Greiner implemented a decision-tree approach to investigate the cost-effectiveness between human milk-based fortifiers and cos's milk-based fortifiers in very low birth weight new-borns. They concluded that an exclusive human milk diet is a cost-effective intervention.

1\. Table or Figure should be self-explained. The abbreviation should be noted, e.g. what are DSA, PSA and so on.

2\. Authors mentioned that the health state specific probabilities of complication were either directly calculated or estimated from other studies. It would be good to indicate which is from direct calculation and which is estimated from other studies in the presentation of results/tables.

3\. Some estimates, e.g. health state specific probabilities, the efficacy of EHMD and so on, were not directly calculated based on the sample but estimated from other studies. For those from other studies, please comment on how compatible or generalizable to the German population.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

4 Nov 2019

Reviewer \#1:

Thank you very much for taking the time to review our paper and thank you for your constructive feedback. We are grateful you even specified the lines where changes need to be made. Please see below our responses on your comments, which where all included in the new version of the manuscript.

Line 34 : Please provide the expansion of LYG and ICER here

Thank you very much, we added the expansion of LYG and ICER.

Line 48 : need to be BPD instead of BDP

Thank you for noticing this. The typo has been corrected.

Line 108-109 : what is meant by the statement\"in cost scenario for EHMD a ratio of 30/70 is assumed using Prolact+8 (with a ratio of 40/60)\". Why is it assumed as 30/70 when its 40/60

Sorry for this relict of a previous version. The correct ratio is 40/60 and the sentence has been changed accordingly. It now reads as follows:

"In the lower scenario, Prolact+4 is used with a ratio of 20/80ml and in the high cost scenario for EHMD a ratio of 40/60 is assumed using Prolact+8."

Line 115-116 : If there are no available data for the effectiveness of EHMD on neurological sequelae, based on what criteria was the RR of 0.90 assumed

There is no direct evidence for the effectiveness of EHMD on neurological sequelae as the manifestation of a neurological impairment will only become evident when the children are at around school age. But there are studies suggesting that NEC and sepsis are associated with a higher probability of neurological impairment and reducing NEC and sepsis thus also leads to a reduction in neurological impairments (please see references below). We therefore included -- from our perspective -- a conservative value of 0.90 for neurological sequelae. Please let us know if this acceptable in your opinion.

Roze et al. 2011 Functional Impairments at School Age of Children With Necrotizing Enterocolitis or Spontaneous Intestinal Perforation, Pediatric Research 70(6):619-625.

van der Ree et al. 2011, Functional impairments at school age of preterm born children with late-onset sepsis, Early Human Development 87:821-826.

Ehrenkranz et al. 2006, Growth in the Neonatal Intensive Care Unit Influences Neurodevelopmental and Growth Outcomes of Extremely Low Birth Weight Infants, Pediatrics 117(4):1253-1261.

Line 136-138 : What was the process used to calculate the LOS data based on birth weight? What is the adjustment factor and how was it arrived at?

Unfortunately, there is no data source available that would allow estimating the LOS for the different conditions (NEC, sepsis, etc.) stratified by age. However, there are two different data sources available that give information about the marginal distributions of the LOS by birth weight and the LOS for each of the conditions, respectively. We used the data source giving the LOS by birth weight to calculate the ratio of the LOS for each birth weight category, compared to the LOS for all new-borns with a birth weight between 500g and 1499g.The LOS for the different conditions were then multiplied by this factor. We added some more information on the calculation and the sentence now reads as follows:

"As the ICD-specific LOS data were not available stratified by birth weight, adjustment factors have been calculated from another German data source on LOS of very low birth weight infants by calculating the ratio of the LOS of the different birth weight categories and the overall LOS of all new-borns with a birth weight between 500g and 1499g."

Line 160 : Put WTP in parenthesis here so that the reader can recognize what it stands for later in the manuscript.

The abbreviation WTP for willingness-to-pay has been added.

Line 177 - its showing both Table 2Table 1. which one is it? Table 2?

Sorry, this seems to be a problem with the automated numbering in Word. We removed all automated fields. It should read as Table 2.

Table 2 : Please add \"for the base case\" in the legend.

We amended the table caption as you suggested.

Reviewer \#2:

1\. Table or Figure should be self-explained. The abbreviation should be noted, e.g. what are DSA, PSA and so on.

Thank you for this suggestion. We added the explanations of the abbreviations used in the table and figures in the respective captions.

2\. Authors mentioned that the health state specific probabilities of complication were either directly calculated or estimated from other studies. It would be good to indicate which is from direct calculation and which is estimated from other studies in the presentation of results/tables.

Thank you for this comment. We included a sentence in the methods section that states the probabilities which were estimated from other studies. The sentence now reads: "When this was not possible (i.e. for the probabilities of NEC alone and RoP given NEC and sepsis, respectively), relative risks have been calculated from studies \[26, 27\] and were applied to German datasets to retrieve health state specific complication probabilities." We also added asterisks to parameters in table 1 for which other studies were used.

3\. Some estimates, e.g. health state specific probabilities, the efficacy of EHMD and so on, were not directly calculated based on the sample but estimated from other studies. For those from other studies, please comment on how compatible or generalizable to the German population.

You are correct, that the transferability of the results from the other studies is limited. We amended the limitations section in the discussion to put more emphasis on this point. The discussion starts as follows:

"The results of this modelling study need to be interpreted in the light of several limitations. First of all, the study population of the clinical studies on EHMD efficacy is from the US and does not entirely match the German model population by the clinical complications and birth weight. The results for the sub-groups of the model population corresponding to the birth weights of the clinical studies were very similar to the overall cost-effectiveness (€35,464 vs. €34,016 per LYG, respectively), but it remains unclear if the effectiveness estimates can be transferred to new-borns with birth weights below 750g or above 1,250g. The transferability of our results is also limited with regard to other countries due to the specific NEC rates, the German reimbursement scheme for inpatient costs and the cost of human milk and fortifiers in Germany."
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An Exclusive Human Milk Diet for Very Low Birth Weight Newborns -- a Cost-Effectiveness and EVPI Study for Germany

PONE-D-19-22800R1

Dear Dr. Scholz,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Prem Singh Shekhawat, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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An Exclusive Human Milk Diet for Very Low Birth Weight Newborns -- a Cost-Effectiveness and EVPI Study for Germany

Dear Dr. Scholz:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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Dr. Prem Singh Shekhawat

Academic Editor
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